BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29402376)

  • 1. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer.
    Ghaneh P; Hanson R; Titman A; Lancaster G; Plumpton C; Lloyd-Williams H; Yeo ST; Edwards RT; Johnson C; Abu Hilal M; Higginson AP; Armstrong T; Smith A; Scarsbrook A; McKay C; Carter R; Sutcliffe RP; Bramhall S; Kocher HM; Cunningham D; Pereira SP; Davidson B; Chang D; Khan S; Zealley I; Sarker D; Al Sarireh B; Charnley R; Lobo D; Nicolson M; Halloran C; Raraty M; Sutton R; Vinjamuri S; Evans J; Campbell F; Deeks J; Sanghera B; Wong WL; Neoptolemos JP
    Health Technol Assess; 2018 Feb; 22(7):1-114. PubMed ID: 29402376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
    Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
    J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
    Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
    Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling.
    Gilbert FJ; Harris S; Miles KA; Weir-McCall JR; Qureshi NR; Rintoul RC; Dizdarevic S; Pike L; Sinclair D; Shah A; Eaton R; Clegg A; Benedetto V; Hill JE; Cook A; Tzelis D; Vale L; Brindle L; Madden J; Cozens K; Little LA; Eichhorst K; Moate P; McClement C; Peebles C; Banerjee A; Han S; Poon FW; Groves AM; Kurban L; Frew AJ; Callister ME; Crosbie P; Gleeson FV; Karunasaagarar K; Kankam O; George S
    Health Technol Assess; 2022 Mar; 26(17):1-180. PubMed ID: 35289267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling.
    Meads C; Auguste P; Davenport C; Małysiak S; Sundar S; Kowalska M; Zapalska A; Guest P; Thangaratinam S; Martin-Hirsch P; Borowiack E; Barton P; Roberts T; Khan K
    Health Technol Assess; 2013 Mar; 17(12):1-323. PubMed ID: 23537558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer.
    Lytras D; Connor S; Bosonnet L; Jayan R; Evans J; Hughes M; Garvey CJ; Ghaneh P; Sutton R; Vinjamuri S; Neoptolemos JP
    Dig Surg; 2005; 22(1-2):55-61; discussion 62. PubMed ID: 15838173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.
    Kim MJ; Lee KH; Lee KT; Lee JK; Ku BH; Oh CR; Heo JS; Choi SH; Choi DW
    Pancreas; 2012 Aug; 41(6):897-903. PubMed ID: 22699202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness.
    Heinrich S; Goerres GW; Schäfer M; Sagmeister M; Bauerfeind P; Pestalozzi BC; Hany TF; von Schulthess GK; Clavien PA
    Ann Surg; 2005 Aug; 242(2):235-43. PubMed ID: 16041214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of 18F-FDG positron emission tomography/computed tomography on the pre-operative staging and the management of patients with pancreatic carcinoma.
    Wang XY; Yang F; Jin C; Guan YH; Zhang HW; Fu DL
    Hepatogastroenterology; 2014 Oct; 61(135):2102-9. PubMed ID: 25722999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
    Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An economic evaluation of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.
    Auguste P; Barton P; Hyde C; Roberts TE
    Health Technol Assess; 2011 Apr; 15(18):iii-iv, 1-54. PubMed ID: 21524363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
    Tomimaru Y; Takeda Y; Tatsumi M; Kim T; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Kitagawa T; Nagano H; Umeshita K; Wakasa K; Doki Y; Mori M
    Oncol Rep; 2010 Sep; 24(3):613-20. PubMed ID: 20664965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
    Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW
    ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography-CT, and CA 19-9 levels in detecting recurrent pancreatic adenocarcinoma.
    Hamidian Jahromi A; Sangster G; Zibari G; Martin B; Chu Q; Takalkar A; Shi R; Shokouh-Amiri H
    JOP; 2013 Jul; 14(4):466-8. PubMed ID: 23846950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of 18F-FDG PET/CT, Multidetector CT, and MR Imaging in the Diagnosis of Pancreatic Cysts: A Prospective Single-Center Study.
    Kauhanen S; Rinta-Kiikka I; Kemppainen J; Grönroos J; Kajander S; Seppänen M; Alanen K; Gullichsen R; Nuutila P; Ovaska J
    J Nucl Med; 2015 Aug; 56(8):1163-8. PubMed ID: 26045314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
    Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
    Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.